TRENDLINE

Regulatory Uncertainty and the Future of Cell Therapy

Getty Images

Despite several advances, cell therapy investment has slumped since peaking in 2021. FDA staff cuts and turnover at the office regulating cell therapies have increased pressure on developers, many of which had already shifted development strategies or restructured.

Access now to discover stories including:

FDA meeting gives window into cell and gene therapy field’s angst
Cell and gene therapy face fresh uncertainty as two more top FDA officials depart
Abeona cell therapy approved by FDA for rare skin condition

For these insights and more, access the Trendline.

This Trendline is independently produced by our journalists. The support of our sponsors makes this journalism possible. Want to learn about sponsorship opportunities? Contact us directly at advertising@industrydive.com.

Want to reach 108,000+ biopharma executives with your own message? Get the media kit or contact us directly at advertising@industrydive.com.

About this email: You are receiving this message as part of your complimentary newsletter subscription to BioPharma Dive. If you no longer wish to receive the daily newsletter, you can switch to a weekly subscription or unsubscribe. See our full privacy policy. BioPharma Dive is a product of TechTarget, Inc. and its subsidiaries, 275 Grove St. Newton, MA, 02466